Current Diabetes Reports

, Volume 6, Issue 6, pp 417–423 | Cite as

An update on autonomic neuropathy affecting the gastrointestinal tract

  • Liza K. Phillips
  • Christopher K. Rayner
  • Karen L. Jones
  • Michael HorowitzEmail author


Gastrointestinal symptoms and disordered gut motility occur frequently in the diabetic population and are generally regarded as manifestations of gastrointestinal "autonomic dysfunction," although the relationships between both symptoms and dysmotility with abnormal cardiovascular autonomic function are weak. It is now recognized that the blood glucose concentration is both a determinant of and determined by gastrointestinal function. An improved de.nition of the underlying pathophysiology should facilitate the development of therapies that are targeted more effectively.


Gastric Emptying Cisapride Gastroparesis Autonomic Neuropathy Tegaserod 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Forster J, Damjanov I, Lin Z, et al.: Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J Gastrointest Surg 2005, 2:588–590. An important study identifying the potential role of the ICC in diabetic gastroparesis. Full-thickness antral wall biopsies were obtained from 14 gastroparetic patients at the time of surgery for gastric electrical stimulation. A reduction or absence in the number of ICC was evident in a subset of patients, which correlated with greater motility disturbance, more symptoms, and a poorer response to therapy.Google Scholar
  2. 2.
    Smout AJ: Oesophageal function. In Gastrointestinal Function in Diabetes Mellitus. Edited by Horowitz M, Samsom M. Chichester: John Wiley and Sons; 2004:97–116.CrossRefGoogle Scholar
  3. 3.
    Horowitz M, Dent J, Fraser R, et al.: Role and integration of mechanisms controlling gastric emptying. Dig Dis Sci 1994, 39:S7-S13.CrossRefGoogle Scholar
  4. 4.
    Horowitz M, Jones KL, Akkermans LMA, Samson M: Gastric function. In Gastrointestinal Function in Diabetes Mellitus. Edited by Horowitz M, Samsom M. Chichester: John Wiley and Sons; 2004:117–176.CrossRefGoogle Scholar
  5. 5.
    Horowitz M, Edelbroek M, Wishart JM, Straathof JW: Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993, 36:857–862.PubMedCrossRefGoogle Scholar
  6. 6.
    Samson M, Verhagen M: Intestinal function. In Gastrointestinal Function in Diabetes Mellitus. Edited by Horowitz M, Samsom M. Chichester: John Wiley and Sons; 2004:177–217.CrossRefGoogle Scholar
  7. 7.
    Sun WS, Read N: Anorectal function. In Gastrointestinal Function in Diabetes Mellitus. Edited by Horowitz M, Samsom M. Chichester: John Wiley and Sons; 2004:219–246.CrossRefGoogle Scholar
  8. 8.
    Hammer J, Abell T, Cutts T, Talley NJ. Epidemiology of disordered gastrointestinal function and impact of chronic gastrointestinal symptoms on quality of life. In Gastrointestinal Function in Diabetes Mellitus. Edited by Horowitz M, Samsom M. Chichester: John Wiley and Sons; 2004:1–27.CrossRefGoogle Scholar
  9. 9.
    Bytzer PM, Talley NJ, Hammer J, et al.: Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,0000 adults. Arch Intern Med 2000, 161:1989–1996.CrossRefGoogle Scholar
  10. 10.
    Enck P, Rathmann W, Spiekermann M, et al.: Prevalence of gastrointestinal symptoms in diabetic patients and nondiabetic subjects. Z Gastroenterol 1994, 32:637–641.PubMedGoogle Scholar
  11. 11.
    Low PA, Benrud-Lason LM, Sletten DM, et al.: Autonomic symptoms and diabetic neuropathy. A population-based study. Diabetes Care 2004, 27:2942–2947.PubMedCrossRefGoogle Scholar
  12. 12.
    Vinik AI, Maser RE, Mitchell BD, Freeman R: Diabetic autonomic neuropathy. Diabetes Care 2003, 26:1553–1579. A comprehensive review of autonomic neuropathy in diabetes, focusing largely on cardiovascular autonomic neuropathy, but with a concise summary of autonomic neuropathy involving the GI tract.PubMedCrossRefGoogle Scholar
  13. 13.
    Young AA, Edwards GL: Effects of diabetes mellitus on gastrointestinal function in animal models. In Gastrointestinal Function in Diabetes Mellitus. Edited by Horowitz M, Samsom M. Chichester: John Wiley and Sons; 2004:29–95.CrossRefGoogle Scholar
  14. 14.
    Ordog T, Takayama I, Cheung WK, et al.: Remodelling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes 2000, 49:19731–19739.CrossRefGoogle Scholar
  15. 15.
    Horvath VJ, Vittal H, Lorincz A, et al.: Reduced stem cell factor links smooth myopathy and loss of interstitial cells of Cajal in murine diabetic gastroparesis. Gastroenterology 2006, 130:759–770.PubMedCrossRefGoogle Scholar
  16. 16.
    Shotton HR, Lincoln J: Diabetes only affects nitric oxide synthase-containing myenteric neurons that do not contain heme oxygenase 2. Brain Res 2006, 1068:248–256.PubMedCrossRefGoogle Scholar
  17. 17.
    Anitha M, Gondha C, Sutliff R, et al.: GDNF rescues hyperglycaemia-induced diabetic enteric neuropathy through activation of the P13/Akt pathway. J Clin Invest 2006, 116:344–356.PubMedCrossRefGoogle Scholar
  18. 18.
    Yoshida MM, MD, Sumi SM: There are no morphologic abnormalities of the gastric wall or abdominal vagus in patients with diabetic gastroparesis. Gastroenterology 1988, 94:907–914.PubMedGoogle Scholar
  19. 19.
    Gilbey SG, Guy RJ, Jones H, et al.: Diabetes and autonomic neuropathy: an immunological association? Diabet Med 1986, 3:241–245.PubMedCrossRefGoogle Scholar
  20. 20.
    Granberg V, Ejskjaer N, Peakman M, Sunkvist G: Autoantibodies to autonomic nerves associated with cardiac and peripheral autonomic neuropathy. Diabetes Care 2005, 28:1959–1964.PubMedCrossRefGoogle Scholar
  21. 21.
    Jackson MW, Gordon TP, Waterman SA: Disruption of intestinal motility by a calcium channel-stimulating autoantibody in type 1 diabetes. Gastroenterology 2004, 126:819–828.PubMedCrossRefGoogle Scholar
  22. 22.
    He CL, Soffer EE, Ferris CD, et al.: Loss of interstitial cells of Cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology 2001, 121:427–434.PubMedCrossRefGoogle Scholar
  23. 23.
    Ejskjaer NT, Bradley JL, Buxton-Thomas MS, et al.: Novel surgical treatment and gastric pathology in diabetic gastroparesis. Diabet Med 1999, 16:488–495.PubMedCrossRefGoogle Scholar
  24. 24.
    Rayner CK, Jones KL, Samsom M, Horowitz M: Relationships of upper gastrointestinal motor and sensory function with glycaemic control. Diabetes Care 2001, 24:371–381.PubMedCrossRefGoogle Scholar
  25. 25.
    Fraser RJ, Horowitz M, Maddox AF, et al.: Hyperglycaemia slows gastric emptying in type 1 insulin-dependent diabetes mellitus. Diabetologia 1990, 30:675–680.CrossRefGoogle Scholar
  26. 26.
    Schvarcz E, Palmer M, Aman J, et al.: Physiological hyperglycaemia slows gastric emptying in normal subjects and subjects with insulin-dependent diabetes mellitus. Gastroenterology 1997, 113:60–66.PubMedCrossRefGoogle Scholar
  27. 27.
    Russo A, Stevens JE, Chen R, et al.: Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes. J Clin Endocrinol Metab 2005, 90:4489–4495.PubMedCrossRefGoogle Scholar
  28. 28.
    Maximilian B, Barnert J, Wienbeck M: Autonomic dysfunction and gastrointestinal tract. Clin Auton Res 1999, 9:75–81.CrossRefGoogle Scholar
  29. 29.
    Ewing DJ, Martyn CN, Young RJ, Clarke BF: The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985, 8:491–498.PubMedCrossRefGoogle Scholar
  30. 30.
    Phillips WT, Schwartz JG, McMahan CA: Rapid gastric emptying of an oral glucose solution in type 2 diabetic patients. J Nucl Med 1992, 33:1496–1500.PubMedGoogle Scholar
  31. 31.
    Jones KL, Horowitz M, Carney BJ, et al.: Gastric emptying in early non insulin-dependent diabetes mellitus. J Nucl Med 1996, 37:1643–1648.PubMedGoogle Scholar
  32. 32.
    Rayner C, Horowitz M: New management approaches for gastroparesis. Nat Clin Pract Gastroenterol Hepatol 2005, 2:454–462.PubMedCrossRefGoogle Scholar
  33. 33.
    Jones KL, Russo A, Stevens JE, et al.: Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001, 24:1264–1269.PubMedCrossRefGoogle Scholar
  34. 34.
    Horowitz M, Harding PE, Chatterton BE, et al.: Acute and chronic effect of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985, 30:1–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Farup CE, Leidy NY, Murray M, et al.: Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care 1998, 21:1699–1706.PubMedCrossRefGoogle Scholar
  36. 36.
    Abell TL, Bernstein RK, Cutts T, et al.: Treatment of gastroparesis: a multidisciplinary clinical review. The American Motility Task Force on Gastroparesis. Neurogastroenterol Motil 2006, 18:263–283. An excellent overview of the current approach to the management of gastroparesis, including summaries of new and emerging therapies.PubMedCrossRefGoogle Scholar
  37. 37.
    Jones KL, Berry M, Kong MF, et al.: Hyperglycaemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care 1999, 22:339–344.PubMedCrossRefGoogle Scholar
  38. 38.
    Janssens J, Peeters TL, Vantrappen G, et al.: Erythromycin improves delayed gastric emptying in diabetic gastroparesis. N Engl J Med 1990, 332:1028–1031.CrossRefGoogle Scholar
  39. 39.
    Maganti K, Onyemere K, Jones MP: Oral erythromycin and symptomatic relief of gastroparesis: a systemic review. Am J Gastroenterol 2003, 98:259–263.PubMedGoogle Scholar
  40. 40.
    McHugh S, Lico S, Diamant NE: Cisapride vs metoclopramide. An acute study in diabetic gastroparesis. Dig Dis Sci 1992, 37:997–1001.PubMedCrossRefGoogle Scholar
  41. 41.
    Melga P, Mansi C, Ciuchi E, et al.: Chronic administration of levosulpiride and glycaemic control in IDDM patients with gastroparesis. Diabetes Care 1997, 20:55–58.PubMedCrossRefGoogle Scholar
  42. 42.
    Asawaka H, Hayashi I, Fukui T, Tokunga K: Effects of mosapride on glycaemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy. Diabetes Res Clin Pract 2003, 61:175–182.CrossRefGoogle Scholar
  43. 43.
    Murray CD, Martin NM, Patterson M, et al.: Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 2005, 54:1693–1698. This is a double-blind, placebo-controlled, crossover study in 10 diabetic patients requiring insulin. In response to a 2-hour infusion of ghrelin in the context of a euglycemic clamp, gastric emptying as assessed by ultrasound was accelerated in seven of 10 subjects. Ghrelin-based therapies may potentially represent a novel prokinetic class.PubMedCrossRefGoogle Scholar
  44. 44.
    Park MI, Ferber M, Camilleri K, et al.: Effect of atilmotin on gastrointestinal transit in healthy subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil 2006, 18:28–36.PubMedCrossRefGoogle Scholar
  45. 45.
    McCallum RW, Rogel R, Fang JC, et al.: Mitemacil fumarate (GM-611) provided symptomatic relief of diabetic gastroparesis, especially in type 1 diabetics: results of a 12-week, multi-centre, double-blind, placebo controlled, randomized phase 2b study. Gastroenterology 2005, 128:A467.Google Scholar
  46. 46.
    Dishy V, Cohen Pour M, Feldman L, et al.: The effect of sildenafil on gastric emptying in patients with end-stage renal failure and symptoms of gastroparesis. Clin Pharm Ther 2004, 76:281–286.CrossRefGoogle Scholar
  47. 47.
    Stevens JE, Russo A, Delaney CA, et al.: Acute effects of C-peptide on gastric emptying in longstanding type 1 diabetes. Clin Auton Res 2006, 16:55–57.PubMedCrossRefGoogle Scholar
  48. 48.
    Gaber AO, Oxley D, Karas J, et al.: Changes in gastric emptying in recipients of successful combined pancreaskidney transplants. Dig Dis 1991, 9:437–443.PubMedCrossRefGoogle Scholar
  49. 49.
    Lacy BE, Zayat EN, Crowell MD, Schuster MM: Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am J Gastroenterol 2002, 97:1548–1552.PubMedCrossRefGoogle Scholar
  50. 50.
    Lacy BE, Weiser K: Gastric motility, gastroparesis, and gastric stimulation. Surg Clin North Am 2005, 85:967–987.PubMedCrossRefGoogle Scholar
  51. 51.
    Forster J, Sarosiek I, Delcore R, et al.: Gastric pacing is a new surgical treatment for gastroparesis. Am J Surg 2001, 182:676–681.PubMedCrossRefGoogle Scholar
  52. 52.
    Forster J, Sarosiek I, Lin Z, et al.: Further experience with gastric stimulation to treat refractory gastroparesis. Am J Surg 2003, 186:690–695.PubMedCrossRefGoogle Scholar
  53. 53.
    Abell T, McCallum R, Hocking M, et al.: Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 2003, 125:421–428.PubMedCrossRefGoogle Scholar
  54. 54.
    Lin Z, Sarosiek I, Forster J, McCallum RW: Symptom responses, long-term outcomes and adverse events beyond 3 years of high-frequency gastric electrical stimulation for gastroparesis. Neurogastroenterol Motil 2006, 18:18–27. This study provides the most comprehensive follow-up of patients receiving gastric electrical stimulation. Data were collected at baseline, 1 year, and beyond 3 years in 55 patients (39 with diabetes). An improvement in symptom score and glycemic control, as well as a reduction in hospitalization and prokinetic medications, was seen. The study was uncontrolled.PubMedCrossRefGoogle Scholar
  55. 55.
    Abell T, Al-Juburi A, Bashed H, Miroch A: 13 years, 214 patients and over 5000 patient months: a long term report on gastric electric stimulation. Gastroenterology 2005, 50:1328–1334.Google Scholar
  56. 56.
    Lin Z, Forster J, Sarosiek I, McCallum RW: Treatment of diabetic gastroparesis by high-frequency nerve stimulation. Diabetes Care 2004, 27:1071–1076.PubMedCrossRefGoogle Scholar
  57. 57.
    Horowitz M, Jones KL, Rayner CK, Read NW: "Gastric" hypoglycaemia—an important concept in diabetes management. Neurogastroenterol Motil 2006, 18:405–407.PubMedCrossRefGoogle Scholar
  58. 58.
    Gallwitz B: Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat Endocrinol 2005, 4:361–370.PubMedCrossRefGoogle Scholar
  59. 59.
    Meier JJ, Kemmeries G, Holst JJ, et al.: Erythromycin antagonises the deceleration of gastric emptying by glucagon-like-peptide-1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 2005, 54:2212–2218.PubMedCrossRefGoogle Scholar
  60. 60.
    Battle WM, Snape WJ Jr, Alavi A, et al.: Colonic dysfunction in diabetes mellitus. Gastroenterology 1980, 79:1217–1221.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Liza K. Phillips
  • Christopher K. Rayner
  • Karen L. Jones
  • Michael Horowitz
    • 1
    Email author
  1. 1.Discipline of MedicineUniversity of Adelaide, Royal Adelaide HospitalNorth Terrace, AdelaideAustralia

Personalised recommendations